Frontiers in Molecular Neuroscience
December 24, 2021
Lynette A. Desouza, Madhurima Benekareddy, Sashaina E. Fanibunda et al.
46 citations
Psychedelic compounds that target the 5-HT 2A receptor are reported to evoke psychoplastogenic effects, including enhanced dendritic arborization and synaptogenesis. Transcriptional regulation of neuronal plasticity-associated genes is implicated in the cytoarchitectural effects of serotonergic psychedelics, however, the transcription factors that drive this regulation are poorly elucidated....
Life
December 23, 2021
Nikola Tatalović, Teodora Vidonja Uzelac, Milica Mijović et al.
8 citations
Ibogaine induces rapid changes in cellular energetics followed by the elevation of antioxidant activities. As shown earlier in male rats, ibogaine treatment with both 1 and 20 mg/kg b.w. per os led to significant glycogenolytic activity in the liver. In this work, female rats treated with the same doses of ibogaine per os displayed lower liver glycogenolytic activity relative to males,...
Psychiatriki
December 20, 2021
Τheodosios Ε Christodoulakis
1 citation
Τhe Food and Drug Administration (FDA) approval of the use of S-ketamine in the form of nasal spray for the treatment of treatment-resistant depression, launched a new category of therapeutic agents in psychiatry. A well-known class of substances, psychedelics, are introduced with a 30-year delay in the treatment of mental disorders. Intravenous ketamine infusion has been studied in the...
Journal of Palliative Medicine
December 20, 2021
Kyle Quirk, Maximillian H. Stevenson
Buprenorphine (BUP) can be a safe and effective alternative to traditional opioids for many patients with chronic pain. For patients on higher doses of opioids, rotation to BUP is complicated by the requirement of an opioid-free interval or withdrawal during the transition. Microdosing inductions, in which BUP is gradually titrated, while full agonist opioids are continued, are a viable...
Psychiatriki
December 20, 2021
Grigorios N. Karakatsoulis, Eva-Maria Tsapakis, Konstantinos Ν. Fountoulakis
1 citation
Treatment-Resistant Depression (TRD) calls for the development of effective interventions for mood elevation and stabilization. Recently, both ketamine and its S-enantiomer (esketamine) have been investigated with successful clinical trials demonstrating effectiveness in TRD. More specifically, in 2019, intranasally administered esketamine, as opposed to the more effective intravenous ketamine,...
medRxiv
December 17, 2021
Anders S. Olsen, Anders Lykkebo-Valløe, Brice Ozenne et al.
4 citations
preprint
Abstract Background Psilocin, the neuroactive metabolite of psilocybin, is a serotonergic psychedelic that induces an acute altered state of consciousness, evokes lasting changes in mood and personality in healthy individuals, and has potential as an antidepressant treatment. Examining the acute effects of psilocin on resting-state dynamic functional connectivity implicates network-level...
Frontiers in Psychiatry
December 17, 2021
John R. Kelly, Claire M. Gillan, Jack Prenderville et al.
66 citations
Accumulating clinical evidence shows that psychedelic therapy, by synergistically combining psychopharmacology and psychological support, offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and/or maladaptive habitual patterns of emotion, cognition and behavior, notably, depression (MDD), treatment resistant depression (TRD) and addiction disorders,...
Neuroscience & Biobehavioral Reviews
December 16, 2021
Igor Elman, Amanda C. Pustilnik, David Borsook
26 citations
Basic pain research has shed light on key cellular and molecular mechanisms underlying nociceptive and phenomenological aspects of pain. Despite these advances, we still yearn for the discovery of novel therapeutic strategies to address the unmet needs of about 70 % of chronic neuropathic pain patients whose pain fails to respond to opioids as well as to other conventional analgesic agents....
December 15, 2021
Vince Polito, Paul Liknaitzky
2 citations
preprint
The use of low doses of psychedelic substances (microdosing) is attracting increasing interest. This systematic review summarises all empirical microdosing research to date, including a set of infrequently cited studies that took place prior to prohibition. Specifically, we reviewed 44 studies published between 1955 and 2021, and summarised reported effects across six categories: mood and...
Journal of Psychedelic Studies
December 15, 2021
Malin V. Uthaug, Natasha L. Mason, Martha N. Havenith et al.
15 citations
Abstract Background Holotropic breathwork (Grof ® Breathwork), was developed by Stanislav Grof and Christina Grof as a ‘non-drug’ alternative technique to evoke altered states of consciousness (ASC). Interestingly, although HBW has been anecdotally reported to evoke experiences and mental health effects corresponding to those of psychedelic substances, the scientific literature on the matter is...